<DOC>
	<DOCNO>NCT00783796</DOCNO>
	<brief_summary>To evaluate safety effectiveness 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System ( XIENCE V® EECSS ) improve coronary luminal diameter subject ischemic heart disease due maximum two de novo native coronary artery lesion small vessel , different epicardial vessel .</brief_summary>
	<brief_title>SPIRIT Small Vessel Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>General Inclusion Criteria 1 . Subject must least 18 year age . 2 . Subject legally authorize representative must provide write informed consent prior study related procedure . 3 . Subject must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) . 4 . Subject must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Subject must agree participate clinical study period one year follow index procedure . Angiographic Inclusion Criteria 1 . One target two ( two target one target one nontarget ) de novo lesion ( ) , different epicardial vessel . 2 . If two target lesion one target one nontarget lesion , lesion must satisfy angiographic eligibility criterion . 3 . The target lesion ( ) nontarget lesion must locate major artery branch visually estimate diameter stenosis ≥50 % &lt; 100 % TIMI flow ≥1 . 4 . The target lesion ( ) nontarget lesion must locate native coronary artery reference vessel diameter visual estimation : Target Lesion : ≥ 2.25 mm &lt; 2.5 mm treatment 2.25 mm XIENCE V® EECS . Nontarget Lesion : ≥2.5 mm ≤4.25 mm treatment commercial XIENCE V® EECS . 5 . The target lesion ( ) nontarget lesion must locate native coronary artery lesion length visual estimation ≤28 mm . General Exclusion Criteria 1 . Subject know diagnosis acute myocardial infarction ( AMI ) precede index procedure ( CKMB ( creatine kinase myocardialband isoenzyme ) ≥2 time upper limit normal ) CK CKMB level return within normal limit time procedure . 2 . The subject currently experience clinical symptom consistent new onset AMI , nitrateunresponsive prolong chest pain ischemic ECG change . 3 . Subject current unstable cardiac arrhythmia associate hemodynamic instability . 4 . Subject know leave ventricular ejection fraction ( LVEF ) &lt; 30 % ( LVEF may obtain time index procedure value unknown necessary ) . 5 . Subject receive coronary brachytherapy epicardial vessel . 6 . Subject receive organ transplant wait list organ transplant . 7 . Subject receive schedule receive chemotherapy malignancy within 30 day prior within one year index procedure . 8 . Subject receive schedule receive plan radiation therapy chest mediastinum . 9 . Subject receive immunosuppressant therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus etc. ) . 10 . Subject receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) . 11 . Subjects require Low Molecular Weight Heparin ( LMWH ) postprocedure . 12 . Subject know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , everolimus , cobalt , chromium , nickel , tungsten , acrylic fluoropolymers contrast sensitivity adequately premedicated . 13 . Elective surgery plan within 12 month procedure require discontinue either aspirin clopidogrel . 14 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC ( white blood cell ) &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) . 15 . Subject know renal insufficiency ( eg , serum creatinine level ≥ 2.5 mg/dL , dialysis ) . 16 . Subject history bleed diathesis coagulopathy refuse blood transfusion . 17 . Subject cerebrovascular accident/stroke transient ischemic neurological attack ( TIA ) within past six month . 18 . Subject significant gastrointestinal significant urinary bleed within past six month . 19 . Subject extensive peripheral vascular disease precludes safe 6 French sheath insertion . 20 . Subject medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less one year ) . 21 . Subject currently participate another clinical study yet complete primary endpoint . 22 . Pregnant nursing subject plan pregnancy period 1 year follow index procedure . Female subject childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test . Angiographic Exclusion Criteria 1 . Target lesion ( ) nontarget lesion locate within arterial saphenous vein graft distal diseased ( vessel irregularity per angiogram &gt; 20 % stenosed lesion visual estimation ) arterial saphenous vein graft . 2 . Target lesion ( ) nontarget lesion involve bifurcation side branch ≥2 mm diameter and/or ostial lesion &gt; 40 % stenosed visual estimation side branch require protection guide wire , side branch require dilatation . 3 . Total occlusion ( TIMI flow 0 ) , prior cross wire . 4 . Another lesion require revascularization locate epicardial vessel either target nontarget lesion . 5 . Restenotic lesion . 6 . Aortoostial lesion ( within 3 mm aorta junction ) . 7 . Left main location . 8 . Lesion locate within 2 mm origin LAD ( leave anterior descend ) LCX ( leave coronary artery ) 9 . Extreme angulation ( ≥90° ) excessive tortuosity ( ≥ two 45° angle ) proximal within target nontarget lesion . 10 . Heavy calcification proximal within target nontarget lesion ( ) . 11 . Target nontarget vessel contain thrombus indicated angiographic image . 12 . Target lesion ( ) nontarget lesion high probability procedure predilatation stenting require time index procedure treat target nontarget vessel ( ) ( e.g . atherectomy , cut balloon ) . 13 . Target nontarget vessel ( ) previously treat percutaneous intervention ( e.g . balloon angioplasty , stent , cut balloon , atherectomy ) &lt; 9 month prior index procedure . 14 . A vessel intend treat 2.25 mm XIENCE V® EECS commercial size XIENCE V® EECS previously treat type PCI ( percutaneous coronary intervention ) &lt; 90 day prior index procedure . 15 . Additional clinically significant lesion ( ) ( e.g. , % DS ( diameter stenosis ) ≥ 50 % ) present vessel side branch PCI may require &lt; 90 day index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Myocardial ischemia</keyword>
</DOC>